| Citation: |
QI Xiaoguang, QI Chunyan, QIN Boyu, HU Yi, HAN Weidong. Screening and Identification of Key Genes for Clinical Benefit of Immunotherapy on Lung Adenocarcinoma Based on TCGA Database[J]. Cancer Research on Prevention and Treatment, 2020, 47(11): 839-845. DOI: 10.3971/j.issn.1000-8578.2020.20.0115
|
To identify key biomarkers for predicting the response to immunotherapy and elucidate the possible underlying mechanism in lung adenocarcinoma based on whole-genome sequencing.
Data set of MSKCC (Science 2015) with lung adenocarcinoma from TCGA database were downloaded. According to the duration time of response to immunotherapy, two groups were divided: durable clinical benefit (DCB) group and non-durable clinical benefit (Non-DCB) group. The differences in gene mutation spectrum between the two groups were analyzed. The key genes and underlying biological functions of immunotherapy for lung adenocarcinoma were further analyzed.
There were differences in gene mutation spectrum between the DCB group and the Non-DCB group. In the DCB group, these key genes were mainly involved in Ca signaling pathway, Rap1 and PI3K-AKT pathways. The top 6 hub genes (KRAS, PPP2CB, CDC20, DYNC1I2, BRCA1 and AKAP9) were screened using the PPI network analysis. CDC20 and BRCA1 were associated with the prognosis of lung adenocarcinoma patients.
The hub genes involved in the DCB group might be important to guide the classification of immune signature and improve precision immunotherapy for lung adenocarcinoma. In addition, CDC20 and BRCA1 might be potential therapeutic targets for immunotherapy of lung adenocarcinoma.
| [1] |
Suresh K, Naidoo J, Lin CT, et al. Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities[J]. Chest, 2018, 154(6): 1416-1423. doi: 10.1016/j.chest.2018.08.1048
|
| [2] |
Haanen JB, Robert C. Immune Checkpoint Inhibitors[J]. Prog Tumor Res, 2015, 42: 55-66. http://esmoopen.bmj.com/lookup/external-ref?access_num=25823918&link_type=MED&atom=%2Fesmoopen%2F2%2F4%2Fe000247.atom
|
| [3] |
Khan M, Lin J, Liao G, et al. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials[J]. Medicine (Baltimore), 2018, 97(33): e11936. doi: 10.1097/MD.0000000000011936
|
| [4] |
Janakiram M, Pareek V, Cheng H, et al. Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies[J]. Immunotherapy, 2016, 8(7): 809-819. doi: 10.2217/imt-2016-0001
|
| [5] |
Lantuejoul S, Damotte D, Hofman V, et al. Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma[J]. J Thorac Dis, 2019, 11(Suppl 1):S89-S101.
|
| [6] |
Jang HJ, Lee HS, Ramos D, et al. Transcriptome-based molecular subtyping of non-small cell lung cancer may predict response to immune checkpoint inhibitors[J]. J Thorac Cardiovasc Surg, 2019, 159(4): 1589-1610. http://www.researchgate.net/publication/337174405_Transcriptome-based_Molecular_Subtyping_of_Non-Small_Cell_Lung_Cancer_may_Predict_Response_to_Immune_Checkpoint_Inhibitors
|
| [7] |
Rizvi H, Sanchez-Vega F, La K, et al. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing[J]. J Clin Oncol, 2018, 36(7): 633-641.. doi: 10.1200/JCO.2017.75.3384
|
| [8] |
Gandara DR, Paul SM, Kowanetz M, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab[J]. Nat Med, 2018, 24(9):1441-1448. doi: 10.1038/s41591-018-0134-3
|
| [9] |
Wang S, Chen B, Zhu Z, et al. CDC20 overexpression leads to poor prognosis in solid tumors: A system review and meta-analysis[J]. Medicine (Baltimore), 2018, 97(52): e13832. doi: 10.1097/MD.0000000000013832
|
| [10] |
Alfarsi LH, Ansari RE, Craze ML, et al. CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy[J]. Breast Cancer Res Treat, 2019, 178(3): 535-544. doi: 10.1007/s10549-019-05420-8
|
| [11] |
Zhang Q, Huang H, Liu A, et al. Cell division cycle 20 (CDC20) drives prostate cancer progression via stabilization of β-catenin in cancer stem-like cells[J]. EBio Medicine, 2019, 42: 397-407. http://www.ncbi.nlm.nih.gov/pubmed/30904606
|
| [12] |
Cheng S, Castillo V, Sliva D, et al. CDC20 associated with cancer metastasis and novel mushroom-derived CDC20 inhibitors with antimetastatic activity[J]. Int J Oncol, 2019, 54(6): 2250-2256. http://www.researchgate.net/publication/332512404_CDC20_associated_with_cancer_metastasis_and_novel_mushroom-derived_CDC20_inhibitors_with_antimetastatic_activity
|
| [13] |
Zhang MY, Liu XX, Li H, et al. Elevated mRNA Levels of AURKA, CDC20 and TPX2 are associated with poor prognosis of smoking related lung adenocarcinoma using bioinformatics analysis[J]. Int J Med Sci, 2018, 15(14): 1676-1685. doi: 10.7150/ijms.28728
|
| [14] |
Yi J, Wei X, Li X, et al. A Genome-Wide Comprehensive Analysis of Alterations in Driver Genes in Non-Small-Cell Lung Cancer[J]. Anticancer Drugs, 2018, 29(1): 10-18. doi: 10.1097/CAD.0000000000000571
|
| [15] |
Zhang Y, Wang H, Wang J, et al. Global Analysis of Chromosome 1 Genes Among Patients With Lung Adenocarcinoma, Squamous Carcinoma, Large-Cell Carcinoma, Small-Cell Carcinoma, or Non-Cancer[J]. Cancer Metastasis Rev, 2015, 34(2): 249-264. doi: 10.1007/s10555-015-9558-0
|
| [16] |
Jan Budczies, Carsten Denkert, Balázs Győrffy, et al. Chromosome 9p Copy Number Gains Involving PD-L1 Are Associated With a Specific Proliferation and Immune-Modulating Gene Expression Program Active Across Major Cancer Types[J]. BMC Med Genomics, 2017, 10(1): 74. doi: 10.1186/s12920-017-0308-8
|
| [17] |
Lee A, Moon BI, Kim TH. BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies[J]. Ann Lab Med, 2020, 40(2): 114-121. doi: 10.3343/alm.2020.40.2.114
|
| [18] |
Wang B, Cao C, Liu X, et al. BRCA1-associated protein inhibits glioma cell proliferation and migration and glioma stem cell self-renewal via the TGF-β/PI3K/AKT/mTOR signalling pathway[J].Cell Oncol (Dordr), 2020, 43(2): 223-235. doi: 10.1007/s13402-019-00482-8
|
| [19] |
Li AG, Murphy EC, Culhane AC, et al. BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation[J]. Proc Natl Acad Sci U S A, 2018, 115(41):E9600-E9609. doi: 10.1073/pnas.1807112115
|
| [20] |
Sun X, Cui F, Yin H, et al. Association between EGFR mutation and expression of BRCA1 and RAP80 in non-small cell lung cancer[J].Oncol Lett, 2018, 16(2): 2201-2206.
|
| [21] |
Leng XF, Chen MW, Xian L, et al. Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy[J]. J Exp Clin Cancer Res, 2012, 31(1): 25. doi: 10.1186/1756-9966-31-25
|
| [22] |
Wood K, Hensing T, Malik R, et al. Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review[J]. JAMA Oncol, 2016, 2(6): 805-812. doi: 10.1001/jamaoncol.2016.0405
|
| [1] | LU Hui, XIE Zhengyuan. Research Progress in Noninvasive Early Diagnosis of Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2023, 50(1): 75-80. DOI: 10.3971/j.issn.1000-8578.2023.22.0642 |
| [2] | ZHU Xiaoli, XU Lu. Research Progress of Markers Related to Early Diagnosis of Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(9): 875-879. DOI: 10.3971/j.issn.1000-8578.2022.21.1483 |
| [3] | FENG Yangchun, XU Yi, HUANG Yanchun. Application of Cluster Analysis and Discriminant Analysis in Six Kinds of Lung Cancer Tumor Markers[J]. Cancer Research on Prevention and Treatment, 2015, 42(03): 266-269. DOI: 10.3971/j.issn.1000-8578.2015.03.012 |
| [4] | FAN Guo-yu, WU Xiao-kui, LI Chun-guo. Diagnosis Value of Tumor Markers for Malignant Pleural Effusions[J]. Cancer Research on Prevention and Treatment, 2011, 38(04): 434-436. DOI: 10.3971/j.issn.1000-8578.2011.04.018 |
| [5] | LI Wen-li, ZHAN Shu-hui, LV Mei. Re-evaluation of Multi-tumor Marker Protein Biochip Detective System in Diagnosis of Primary Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2011, 38(03): 294-297. DOI: 10.3971/j.issn.1000-8578.2011.03.014 |
| [6] | YIN Cheng-hong, WEN Yan, REN Jiang-bo, DONG Zhong, LI Jia, WAN GBao-en. Combined Different Tumor Markers in Detecting 50 Primary Hepatic Carcinoma Cases[J]. Cancer Research on Prevention and Treatment, 2005, 32(08): 502-504. DOI: 10.3971/j.issn.1000-8578.3297 |
| [7] | QU Hong-yan, PANG DA, XUE Ying-wei, et al, . Diagnosis and treatment of spleen tumor[J]. Cancer Research on Prevention and Treatment, 2002, 29(04): 316-316. DOI: 10.3971/j.issn.1000-8578.3303 |
| [8] | CAI Xiao-qing, LI Wen-guang. The diagnosis and treatment of the bladder mixed tumor[J]. Cancer Research on Prevention and Treatment, 2002, 29(02): 133-134. DOI: 10.3971/j.issn.1000-8578.941 |
| [9] | XUE Jian-ping, WANG Xian-guang, ZHU Hu, et al, . The Experimental Study of the Use of Examining SerumTumor-specific Growth Factor (TSGF) in the Preceding Diagnosis of Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2001, 28(06): 467-468. DOI: 10.3971/j.issn.1000-8578.479 |
| [10] | LI De-ren, JI Bing-wen. The Clinical Value of Tumor Makers in the Diagnosis, Prediction Response to Chemotherapy and Prognosis in Human Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2001, 28(03): 209-211. DOI: 10.3971/j.issn.1000-8578.2156 |
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: